US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

18.59

-0.1100-0.59%

Post-market: 18.590.00000.00%16:10 EST

Volume:198.30K

Turnover:3.66M

Market Cap:52.02M

PE:- -

High:18.69

Open:18.32

Low:18.16

Close:18.70

52wk High:105.60

52wk Low:14.59

Shares:2.80M

Float Shares:2.80M

Volume Ratio:0.59

T/O Rate:7.09%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novo Nordisk A/S Stock Rises Wednesday, Underperforms Market

Novo Resources Updates Corporate Presentation to Showcase Evolving Gold Strategy

Novo Nordisk Expands Obesity Pipeline With New Phase 2 Trial for UBT251

Dr. Reddy's Looks to Launch Generic Wegovy at 60% Discount, Reuters Reports

MT Newswires Live

Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable

MT Newswires Live

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Novo Nordisk A/S Stock Falls Monday, Underperforms Market

Novo Nordisk A/S Stock Rises Friday, Outperforms Market

Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care: What Investors Should Know

Novo Nordisk price target lowered to DKK 360 from DKK 415 at Berenberg

Sector Update: Health Care Stocks Higher Thursday Afternoon

MT Newswires Live

Market Chatter: Novo Nordisk to Manufacture Wegovy in Ireland Facility

MT Newswires Live

Novo Nordisk Expands GLP-1 Ambitions With Completed Liver and Alcohol Use Trial

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live

Novo Nordisk Initiates Lawsuit Against Hims as Regulators Scrutinize Compounded GLP-1 Drugs

Jefferies Upgrades Novo Nordisk to Hold From Underperform, Adjusts Price Target to $43.90 From $42.10

MT Newswires Live

Novo Nordisk Expands Irish Plant to Boost Global Market Share with Oral Wegovy

Novo Nordisk upgraded to Hold from Underperform at Jefferies

Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs

Mixed options sentiment in Novo Nordisk with shares down 1.82%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVOX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"Defiance Daily Target 2X Long NVO ETF","latestPrice":18.59,"timestamp":1771448400000,"preClose":18.7,"halted":0,"volume":198302,"hourTrading":{"tag":"盘后","latestPrice":18.59,"preClose":18.59,"latestTime":"16:10 EST","volume":6,"amount":111.53999999999999,"timestamp":1771449008909,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00588235294117644,"floatShares":2798101,"shares":2798101,"eps":0,"marketStatus":"Post-Mkt","change":-0.11,"latestTime":"02-18 16:10:36 EST","open":18.32,"high":18.685,"low":18.162,"amount":3664269.172252,"amplitude":0.027968,"askPrice":18.7,"askSize":640,"bidPrice":18.44,"bidSize":960,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771462800000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":18.7,"sharesOutstanding":2798101,"nav":18.88,"aum":52828146.88,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":18.2514,"preClose":18.7,"latestTime":"09:29 EST","volume":6711,"amount":124756.61085900001,"timestamp":1771424948997,"change":-0.4486,"changeRate":-0.023989,"amplitude":0.02139},"postHourTrading":{"tag":"盘后","latestPrice":18.59,"preClose":18.59,"latestTime":"16:10 EST","volume":6,"amount":111.53999999999999,"timestamp":1771449008909,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.588268,"impliedVol":0.7839,"impliedVolPercentile":0.468},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.588268,"shares":2798101,"dividePrice":0,"high":18.685,"amplitude":0.027968,"preClose":18.7,"low":18.162,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":18.59,"committee":0.2,"eps":0,"divideRate":0,"volume":198302,"delay":0,"ttmEps":0,"open":18.32,"prevYearClose":21.89,"prevWeekClose":18.9,"prevMonthClose":28.89,"prevQuarterClose":21.89,"fiveDayClose":18.63,"twentyDayClose":30.31,"sixtyDayClose":21.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612353440","title":"Novo Nordisk A/S Stock Rises Wednesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2612353440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612353440?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:02","pubTimestamp":1771434120,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S advanced 0.5% to DKK311.30 Wednesday on what proved to be an overall favorable trading session for the stock market, with the OMX Nordic 40 Index rising 1.2% to 2,681.73.This was the stock's second consecutive day of gains.The company closed DKK363.90 below its 52-week high of DKK675.20, which the company reached on February 25, 2025.Trading volume was 4,214,099, compared to the 50-day average trading volume of 7,900,029.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4599","LU1093756325.SGD","BK4532","NVOX","NVOH","LU0154236417.USD","BK4585","NVO","BK4007"],"gpt_icon":1},{"id":"2612188484","title":"Novo Resources Updates Corporate Presentation to Showcase Evolving Gold Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2612188484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612188484?lang=en_us&edition=fundamental","pubTime":"2026-02-18 12:32","pubTimestamp":1771389141,"startTime":"0","endTime":"0","summary":"Novo Resources ( ($TSE:NVO) ) has provided an update. Novo Resources has released an updated corporate presentation, providing investors with an up...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-resources-updates-corporate-presentation-to-showcase-evolving-gold-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-resources-updates-corporate-presentation-to-showcase-evolving-gold-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1093756325.SGD","NVOX","BK4007","LU1093756168.USD","BK4599","BK4532","IE00BZ1G4Q59.USD","NVO.AU","IE00BKVL7J92.USD","BK4585","NVOH","LU0154236417.USD"],"gpt_icon":0},{"id":"2612466155","title":"Novo Nordisk Expands Obesity Pipeline With New Phase 2 Trial for UBT251","url":"https://stock-news.laohu8.com/highlight/detail?id=2612466155","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612466155?lang=en_us&edition=fundamental","pubTime":"2026-02-18 00:30","pubTimestamp":1771345835,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The Novo Nordisk A/S study “A Study Investigating Safety, Tolerability and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-expands-obesity-pipeline-with-new-phase-2-trial-for-ubt251?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-expands-obesity-pipeline-with-new-phase-2-trial-for-ubt251?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","LU1093756168.USD","BK4585","BK4007","BK4532","LU0154236417.USD","BK4588","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4599","NVOX","NVO"],"gpt_icon":0},{"id":"2612946397","title":"Dr. Reddy's Looks to Launch Generic Wegovy at 60% Discount, Reuters Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2612946397","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612946397?lang=en_us&edition=fundamental","pubTime":"2026-02-17 23:17","pubTimestamp":1771341422,"startTime":"0","endTime":"0","summary":"Price: 14.35, Change: +0.21, Percent Change: +1.51","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOH","IE00BKVL7J92.USD","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","RDY","BK4007","BK4599","NVOX","BK4523","LU0348744763.USD","BK4596","BK4585","LU1093756168.USD","LU1093756325.SGD","BK4557","BK4588"],"gpt_icon":0},{"id":"2612502414","title":"Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable","url":"https://stock-news.laohu8.com/highlight/detail?id=2612502414","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612502414?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:14","pubTimestamp":1771337656,"startTime":"0","endTime":"0","summary":"Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0154236417.USD","NVO","BK4585","BK4588","LU1093756168.USD","IE00BZ1G4Q59.USD","NVOH","IE00BKVL7J92.USD","LU1093756325.SGD","NVOX","BK4532","BK4599","BK4007"],"gpt_icon":0},{"id":"2612513724","title":"Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612513724","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612513724?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:56","pubTimestamp":1771329417,"startTime":"0","endTime":"0","summary":"In a report released today, James Gordon CFA from Barclays maintained a Hold rating on Novo Nordisk, with a price target of DKK340.00. Gordon CFA c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-novo-nordisk-0qiu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-novo-nordisk-0qiu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOX","LU1093756168.USD","NVOH","BK4585","NVO","LU1093756325.SGD","BK4599","IE00BZ1G4Q59.USD","BK4532","BK4007","LU0154236417.USD","IE00BKVL7J92.USD","BK4588"],"gpt_icon":0},{"id":"2612248110","title":"Novo Nordisk A/S Stock Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2612248110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612248110?lang=en_us&edition=fundamental","pubTime":"2026-02-17 01:02","pubTimestamp":1771261320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S shed 0.9% to DKK307.65 Monday on what proved to be an overall positive trading session for the stock market, with the OMX Nordic 40 Index rising 0.1% to 2,645.80.The company closed DKK367.55 short of its 52-week high of DKK675.20, which the company reached on February 25, 2025.Trading volume was 2,763,198, compared to the 50-day average trading volume of 7,978,299.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","NVOH","BK4599","NVOX","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","BK4007","BK4532","BK4588"],"gpt_icon":1},{"id":"2611229161","title":"Novo Nordisk A/S Stock Rises Friday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2611229161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611229161?lang=en_us&edition=fundamental","pubTime":"2026-02-14 01:02","pubTimestamp":1771002120,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S rose 1.3% to DKK310.60 Friday on what proved to be an overall unfavorable trading session for the stock market, with the OMX Nordic 40 Index falling 0.2% to 2,643.50.The stock's rise  snapped a two-day losing streak.The company closed DKK364.60 below its 52-week high of DKK675.20, which the company reached on February 25, 2025.Trading volume was 5,552,349, compared to the 50-day average trading volume of 8,025,697.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4599","BK4007","IE00BKVL7J92.USD","LU0154236417.USD","NVOX","BK4588","BK4585","NVOH","BK4532","LU1093756168.USD","NVO","LU1093756325.SGD"],"gpt_icon":1},{"id":"2611161343","title":"Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care: What Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2611161343","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611161343?lang=en_us&edition=fundamental","pubTime":"2026-02-14 00:30","pubTimestamp":1771000218,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) has completed a phase 3 study titled “Efficacy and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-into-youth-diabetes-care-what-investors-should-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-into-youth-diabetes-care-what-investors-should-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOX","LU0154236417.USD","BK4211","NVOH","BK4007","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","BK4532","BK4588","BK4585","BK4599","LU1093756168.USD"],"gpt_icon":0},{"id":"2611971017","title":"Novo Nordisk price target lowered to DKK 360 from DKK 415 at Berenberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2611971017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611971017?lang=en_us&edition=fundamental","pubTime":"2026-02-13 03:10","pubTimestamp":1770923418,"startTime":"0","endTime":"0","summary":"Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 360 from DKK 415 and keeps a Buy rating on the shares. Published first on Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-price-target-lowered-to-dkk-360-from-dkk-415-at-berenberg-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-price-target-lowered-to-dkk-360-from-dkk-415-at-berenberg-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4599","LU1093756325.SGD","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","NVO","NVOX","BK4007","LU1093756168.USD","BK4588"],"gpt_icon":0},{"id":"2611971609","title":"Sector Update: Health Care Stocks Higher Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2611971609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611971609?lang=en_us&edition=fundamental","pubTime":"2026-02-13 02:51","pubTimestamp":1770922307,"startTime":"0","endTime":"0","summary":"Health care stocks edged higher Thursday afternoon, with the NYSE Health Care Index adding 0.1% and the State Street Health Care Select Sector SPDR ETF  up 0.2%.The iShares Biotechnology ETF  fell 0.9%.In corporate news, Novocure  shares jumped past 24% after the firm said the US Food and Drug Administration has approved its Optune Pax wearable medical device to treat adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.Novo Nordisk  is planning to boost its investment in Ireland where it will make its Wegovy weight-loss pill for markets outside the US, Bloomberg reported, citing an interview with Mike Doustdar, the company's CEO. Novo shares were easing 0.3%.Icon  said Thursday its audit committee initiated an internal investigation in late October into the company's accounting practices and controls. The investigation focuses primarily on revenue recognition from fiscal year 2023 through 2025, the company said. Its shares dropped 36%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2362541273.HKD","LU1983260115.SGD","BK4548","LU2244417387.USD","LU1043141123.HKD","BK4532","BK4581","BK4585","LU1043141396.HKD","LU1267930573.SGD","LU0154236417.USD","LU2362540622.SGD","BK7104","BK4121","BK4599","LU0511384066.AUD","LU1093756325.SGD","LU0310800379.SGD","LU1691799644.USD","LU1791710400.SGD","LU0128525929.USD","LU2324357040.USD","LU0187121727.USD","NVCR","IE00BZ1G4Q59.USD","LU0289961442.SGD","LU0426412945.USD","LU2362541513.USD","LU0289739343.SGD","LU1791710582.SGD","LU0994945656.USD","LU0057025933.USD","LU0882574055.USD","BK4534","LU0528227936.USD","ICLR","LU2265009873.SGD","NVOX","LU0708994859.HKD","BK4082","LU0114720955.EUR","IE00BKVL7J92.USD","LU0889566641.SGD","BK4588","LU0069063385.USD","LU0426417589.USD","LU1804176565.USD","LU0728928796.USD","BK4007","LABU","LU0289960550.SGD","LU1267930813.SGD","NVOH","LU1121112475.USD","LU0472753341.HKD","LU0792757196.USD","LU0175139822.USD","XBI","LU1093756168.USD","LU0029864427.USD"],"gpt_icon":1},{"id":"2611150976","title":"Market Chatter: Novo Nordisk to Manufacture Wegovy in Ireland Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2611150976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611150976?lang=en_us&edition=fundamental","pubTime":"2026-02-13 01:16","pubTimestamp":1770916599,"startTime":"0","endTime":"0","summary":"Novo Nordisk  is planning to boost its investment in Ireland where it will make its Wegovy weight-loss pill for markets outside the US, Bloomberg reported Thursday, citing an interview with Mike Doustdar, the company's CEO.The company will expand its facility in Athlone to manufacture the weight-loss drug, Doustdar said.Novo Nordisk didn't immediately respond to MT Newswires' request for comment.Price: 48.17, Change: -0.58, Percent Change: -1.18","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU0154236417.USD","LU1093756325.SGD","NVOH","BK4585","NVOX","BK4599","NVO","LU1093756168.USD","IE00BZ1G4Q59.USD","BK7104","BK4532","IE00BKVL7J92.USD","BK4007"],"gpt_icon":1},{"id":"2611975340","title":"Novo Nordisk Expands GLP-1 Ambitions With Completed Liver and Alcohol Use Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611975340","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611975340?lang=en_us&edition=fundamental","pubTime":"2026-02-13 00:31","pubTimestamp":1770913861,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has completed a phase 2 trial titled “Effects of NNC019...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-expands-glp-1-ambitions-with-completed-liver-and-alcohol-use-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-expands-glp-1-ambitions-with-completed-liver-and-alcohol-use-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","NVOH","BK4590","BK4144","BK4585","BK4007","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOX","IE00BKVL7J92.USD","NVO","BK4588","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2611037973","title":"European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2611037973","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611037973?lang=en_us&edition=fundamental","pubTime":"2026-02-13 00:21","pubTimestamp":1770913314,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 1.22% to 1,824.99 on the S&P Europe Select ADR Index.From continental Europe, th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","IHG","BK7119","BK4111","BK4023","BK7104","IE00BJT1NW94.SGD","LU0109394709.USD","02378","IE0009355771.USD","BK4020","BK4107","BK4162","BK4117","IE00B4R5TH58.HKD","IE00BFXG1179.USD","NVOH","BK4532","PUK","MREO","LU2324357040.USD","CRTO","SNY","EVAX","IE0002141913.USD","BDRX","IE0034235188.USD","BK4599","AKTX","LU1983260115.SGD","LU0320765992.SGD","BK4158","IE00B2B36J28.USD","BK4204","IE00BMPRXR70.SGD","IE00BMPRXN33.USD","BUD","BK4007","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","LU0154236417.USD","NOK","OPRA","PSO","IE00BFMHRM44.USD","BK4082","BK4505","BK4585","BK4142","NVOX","ARGX","LU0889565916.HKD","SLN","BK4139","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","IE00BFTCPJ56.SGD","SNN","LU1093756168.USD","BK4009"],"gpt_icon":1},{"id":"1167256830","title":"Novo Nordisk Initiates Lawsuit Against Hims as Regulators Scrutinize Compounded GLP-1 Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1167256830","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167256830?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:51","pubTimestamp":1770911484,"startTime":"0","endTime":"0","summary":"Novo Nordisk A/S (NVO) shares rose 1% in early trading on Thursday. The company has filed a lawsuit seeking to block Hims & Hers Health Inc. (HIMS) from selling compounded semaglutide. This legal...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","LU1093756325.SGD","NVO","BK4588","IE00BKVL7J92.USD","BK4532","BK4585","HIMS","NVOX","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4007","NVOH","BK4599"],"gpt_icon":1},{"id":"2610192615","title":"Jefferies Upgrades Novo Nordisk to Hold From Underperform, Adjusts Price Target to $43.90 From $42.10","url":"https://stock-news.laohu8.com/highlight/detail?id=2610192615","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610192615?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:50","pubTimestamp":1770900600,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) has an average rating of overweight and mean price target of $58.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","BK4007","BK4599","LU1093756325.SGD","NVO","NVOH","IE00BKVL7J92.USD","BK4532","BK4585","NVOX","LU0154236417.USD","BK7104"],"gpt_icon":0},{"id":"1196362242","title":"Novo Nordisk Expands Irish Plant to Boost Global Market Share with Oral Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=1196362242","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196362242?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:09","pubTimestamp":1770894572,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO.US) plans to increase investment in Ireland to produce an oral version of its blockbuster weight-loss drug Wegovy for markets outside the United States. CEO Mike Dursdal stated that...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","BK4007","IE00BKVL7J92.USD","NVOX","NVO","LU1093756325.SGD","LU0154236417.USD","BK4588","IE00BZ1G4Q59.USD","BK4599","LU1093756168.USD","BK4585","BK4532"],"gpt_icon":1},{"id":"2610941844","title":"Novo Nordisk upgraded to Hold from Underperform at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2610941844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610941844?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:55","pubTimestamp":1770890135,"startTime":"0","endTime":"0","summary":"Jefferies upgraded Novo Nordisk (NVO) to Hold from Underperform with a price target of DKK 275, up from DKK 270. The firm says consensus estimate c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-upgraded-to-hold-from-underperform-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-upgraded-to-hold-from-underperform-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVO","LU0154236417.USD","BK4588","BK4532","NVOH","NVOX","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4599","LU1093756168.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2610194934","title":"Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610194934","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610194934?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:23","pubTimestamp":1770888180,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/12/Novo-Nordisk-Advertising-Logo-On-Facade-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/12/Novo-Nordisk-Advertising-Logo-On-Facade-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50567757/novo-nordisk-ceo-sees-opportunity-for-15-million-new-patients-as-medicare-covers-obesity-drugs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50567757/novo-nordisk-ceo-sees-opportunity-for-15-million-new-patients-as-medicare-covers-obesity-drugs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4532","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756168.USD","BK4585","BK4599","NVOX","BK4588","LU1093756325.SGD","BK4007","NVOH"],"gpt_icon":1},{"id":"2610758950","title":"Mixed options sentiment in Novo Nordisk with shares down 1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610758950","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610758950?lang=en_us&edition=fundamental","pubTime":"2026-02-12 02:15","pubTimestamp":1770833715,"startTime":"0","endTime":"0","summary":"Mixed options sentiment in Novo Nordisk (NVO), with shares down 90c near $48.23. Options volume relatively light with 35k contracts traded and call...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-novo-nordisk-with-shares-down-1-82-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-novo-nordisk-with-shares-down-1-82-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","BK4007","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVO","BK4599","BK4532","NVOH","BK4588","LU1093756168.USD","BK4585","LU1093756325.SGD","NVOX"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":112,"code":"91000000","status":"200"}]}}